The Ipsen Investment Case

Strong execution of the external-innovation strategy Seven transactions completed in 2021 across the three therapeutic areas Oncology Accent Therapeutics METTL3 Preclinical BAKX Therapeutics BKX-001 Preclinical Queen's University FLIP-inhibitor program Preclinical DUA Rare Disease Neuroscience IPSEN Innovation for patient care GENFIT elafibranor Phase III IRLAB mesdopetam Exicure Spherical Nucleic Acids BCH/UOS BoNT/X Phase llb Preclinical Preclinical BCH: Boston Children's Hospital; UOS: University of Stockholm; BoNT/X: a novel botulinum toxin serotype. 9

View entire presentation